CN Patent

CN113423395A — 通过增加血清及血浆epa及dpa水平来降低经他汀治疗的受试者的心血管事件的风险的方法

Assigned to Amarin Pharmaceuticals Ireland Ltd · Expires 2021-09-21 · 5y expired

What this patent protects

在各种实施例中，本发明提供降低处于他汀疗法的受试者的心血管事件的风险的方法，该方法通过向该受试者施用包含约1g至约4g二十碳五烯酸乙酯或其衍生物的医药组合物，通过增加该受试者的血浆及血清EPA水平来达成。

USPTO Abstract

在各种实施例中，本发明提供降低处于他汀疗法的受试者的心血管事件的风险的方法，该方法通过向该受试者施用包含约1g至约4g二十碳五烯酸乙酯或其衍生物的医药组合物，通过增加该受试者的血浆及血清EPA水平来达成。

Drugs covered by this patent

Patent Metadata

Patent number
CN113423395A
Jurisdiction
CN
Classification
—
Expires
2021-09-21
Drug substance claim
No
Drug product claim
No
Assignee
Amarin Pharmaceuticals Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.